Medicalsystem Biotechnology Co., Ltd (SHE:300439)
China · Delayed Price · Currency is CNY 9.81
-0.09 (-0.91%)
Sep 22, 2026, 9:35 AM CST
SHE:300439 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 3,805 | 3,786 | 4,012 | 4,447 | 4,481 | 8,162 | |
Market Cap Growth | -5.26% | -5.65% | -9.77% | -0.77% | -45.10% | 30.24% |
Enterprise Value | 2,851 | 2,927 | 3,217 | 3,671 | 4,153 | 8,093 |
Last Close Price | 9.90 | 9.81 | 10.27 | 11.24 | 11.22 | 20.28 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 57.26 | 59.90 | 15.55 | 17.33 | 22.57 | 45.47 |
Forward PE | - | 17.42 | 17.42 | 17.42 | 17.42 | 17.42 |
PS Ratio | 2.33 | 2.46 | 2.30 | 2.36 | 1.80 | 3.63 |
PB Ratio | 1.27 | 1.28 | 1.37 | 1.64 | 1.78 | 3.41 |
P/TBV Ratio | 1.32 | 1.34 | 1.43 | 1.72 | 1.88 | 3.71 |
P/FCF Ratio | 46.86 | 50.34 | - | 12.59 | 17.13 | 26.02 |
P/OCF Ratio | 16.34 | 14.20 | 10.09 | 7.02 | 7.94 | 15.83 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.75 | 1.90 | 1.85 | 1.95 | 1.67 | 3.60 |
EV/EBITDA Ratio | 18.06 | 19.02 | 7.40 | 9.57 | 10.21 | 19.64 |
EV/EBIT Ratio | - | 530.80 | 13.37 | 15.89 | 17.55 | 33.92 |
EV/FCF Ratio | 35.11 | 38.92 | - | 10.39 | 15.88 | 25.80 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.03 | 0.02 | 0.03 | 0.03 | 0.13 | 0.20 |
Debt / EBITDA Ratio | 0.60 | 0.35 | 0.18 | 0.23 | 0.77 | 1.11 |
Debt / FCF Ratio | 1.17 | 0.79 | - | 0.26 | 1.27 | 1.54 |
Net Debt / Equity Ratio | -0.32 | -0.31 | -0.28 | -0.32 | -0.22 | -0.12 |
Net Debt / EBITDA Ratio | -6.57 | -5.97 | -1.88 | -2.27 | -1.36 | -0.69 |
Net Debt / FCF Ratio | -11.67 | -12.21 | 35.95 | -2.47 | -2.12 | -0.91 |
Asset Turnover | 0.44 | 0.42 | 0.48 | 0.53 | 0.69 | 0.66 |
Inventory Turnover | 4.48 | 3.84 | 3.57 | 4.45 | 7.23 | 5.79 |
Quick Ratio | 2.62 | 2.53 | 2.21 | 2.25 | 1.81 | 1.55 |
Current Ratio | 3.10 | 3.03 | 2.73 | 2.72 | 2.11 | 1.89 |
Return on Equity (ROE) | 2.27% | 2.09% | 9.31% | 9.93% | 8.36% | 9.33% |
Return on Assets (ROA) | -0.10% | 0.09% | 4.18% | 4.08% | 4.12% | 4.36% |
Return on Invested Capital (ROIC) | -0.29% | 0.27% | 11.33% | 10.67% | 10.69% | 9.47% |
Return on Capital Employed (ROCE) | -0.20% | 0.20% | 7.90% | 8.30% | 9.10% | 9.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.80% | 1.67% | 6.43% | 5.77% | 4.43% | 2.20% |
FCF Yield | 2.13% | 1.99% | -0.57% | 7.94% | 5.84% | 3.84% |
Dividend Yield | 0.34% | 0.34% | 1.31% | 1.19% | 0.94% | 0.47% |
Payout Ratio | 42.69% | 82.27% | 20.34% | 19.44% | 25.54% | 50.92% |
Buyback Yield / Dilution | -2.59% | -2.58% | -0.56% | -0.30% | -2.10% | -8.59% |
Total Shareholder Return | -2.26% | -2.25% | 0.75% | 0.90% | -1.16% | -8.13% |